Longtime researcher Predrag Sikiric, who has championed the peptide BPC-157 for decades, is seeing a surge of interest in the compound amid changing federal attitudes toward peptide therapies. The substance, which Sikiric once nicknamed 'substance God help me,' is being reexamined as the Department of Health and Human Services under Secretary Robert F. Kennedy Jr. adopts a more favorable posture toward such treatments.
This shift represents a significant departure from the skepticism that has historically surrounded BPC-157 and similar peptides within mainstream medicine. Kennedy's public endorsement of peptides as therapeutic agents has opened the door for broader investigation and potential clinical application of compounds once dismissed as fringe.
BPC-157 has been studied primarily for its regenerative properties, particularly in healing soft tissue injuries and gastrointestinal damage. Despite decades of research by Sikiric and others, the compound has never undergone large-scale clinical trials required for FDA approval, leaving its efficacy and safety profile debated among medical professionals.
The resurgent interest comes with substantial caveats. Critics warn that embracing unregulated peptides without robust clinical evidence could expose patients to unknown risks, undermining public trust in medical oversight. Sikiric himself acknowledges that while he sees promise in the compound, rigorous science must guide any therapeutic use.
Some researchers argue that the current momentum, driven more by political alignment than by data, risks repeating past mistakes with unproven supplements. They insist that BPC-157's long and contested history demands caution, not celebration.